Document:

Exhibit

Exhibit 10.1
	
					
	Confidential Materials omitted and filed separately with the
Securities and Exchange Commission. Double asterisks denote omissions.

AMENDMENT NO. 2 TO THE SUPPLY AND DISTRIBUTION AGREEMENT
This Amendment No. 2 (this “Amendment”) to the Agreement (defined below) is entered into by and between The Medicines Company, a company with its principal offices located at 8 Sylvan Way, Parsippany, NJ 07054 (“Innovator”), and Sandoz Inc., a Colorado corporation with a corporate address at 100 College Road West, Princeton, NJ 08540 (“Sandoz”), and shall be effective as of the Amendment Effective Date (defined below).  Innovator and Sandoz may hereafter be referred to collectively as the “Parties” and individually as a “Party”.
WHEREAS, the Parties entered into that certain Supply and Distribution Agreement, dated as of July 2, 2015, as amended by Amendment No. 1 to the Supply and Distribution Agreement, dated as of July 16, 2015 (the “Agreement”); and
WHEREAS, the Parties now desire to amend various provisions of the Agreement.
NOW, THEREFORE, in consideration of the mutual promises, covenants and agreements hereinafter set forth, the Parties hereto agree as follows:
		
	1.
	Defined Terms.  Any capitalized terms used herein that are not otherwise defined in this Amendment shall have the meanings ascribed to them in the Agreement. 

		
	2.
	Amendment Effective Date.  The “Amendment Effective Date” means July 1, 2017.

		
	3.
	Schedule A (“Angiomax®”).  Schedule A is hereby amended as follows: 

		
	a.
	Subsection (c) under “Net Profit split” is hereby deleted and replaced with the following:

“(c) [**] percent ([**]%) of the Net Profit if more than two but less than five generic versions of the Innovator Branded Product (including the Product) are offered for sale in the Territory; or”
		
	b.
	In addition, the following are hereby added as new subsections (d) and (e) under “Net Profit split”:

“(d)    [**] percent ([**]%) of the Net Profit if five or more but less than eight generic versions of the Innovator Branded Product (including the Product) are offered for sale in the Territory; or
(e)    [**] percent ([**]%) of the Net Profit if eight or more generic versions of the Innovator Branded Product (including the Product) are offered for sale in the Territory.”

1

		
	c.
	The section entitled “Table 1: Product Cost by Unit Type” is here by deleted and replaced with the following:

“The Product Cost shall be as set forth in the following table:
	
			
	NDC Number
	Unit Type
	Product Cost

	0781-3158-94
	250mg vial
	$[**]

	0781-3158-95
	10 vial carton
	$[**]

Notwithstanding the foregoing, in the event that are eight or more generic versions of the Innovator Branded Product (including the Product) being are offered for sale in the Territory, then the Product Cost shall be:
	
			
	NDC Number
	Unit Type
	Product Cost

	0781-3158-94
	250mg vial
	$[**]

	0781-3158-95
	10 vial carton
	$[**]

”
		
	4.
	Profit Share Adjustment. 

		
	a.
	In addition to the adjustment of the Net Profit split percentages set forth in Paragraphs 3(a) and 3(b) above, within [**] Business Days after the Amendment Effective Date, the Innovator shall issue Sandoz a credit memo for an amount equal to $[**] and Sandoz shall be permitted to set-off any Net Profit payments that become due to the Medicines Company against such credit memo, until the amount of such credit memo has been exhausted in its entirety.

		
	5.
	Full Force and Effect.  Except as expressly provided in this Amendment, this Amendment does not in any way change, modify or delete the provisions of the Agreement (or the Parties’ rights, remedies or obligations thereunder), and all such provisions shall remain in full force and effect. On and after the date of this Amendment, each reference in the Agreement to “this Agreement,” “hereunder,” “hereof,” “herein,” or words of like import, and each reference to the Agreement in any other agreements, documents or instruments executed and delivered pursuant to the Agreement, shall mean and be a reference to the Agreement, as amended by this Amendment.  

2

		
	6.
	Counterparts; Facsimile/PDF Signature.  This Amendment may be executed in one or more counterparts, all of which shall be considered one and the same agreement, and shall become effective when one or more counterparts have been signed by each of the Parties hereto and delivered, in person or by facsimile or electronic image scan, receipt acknowledged in each case, to the other Party to this Amendment. 

		
	7.
	Governing Law.  This Amendment shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to the conflicts of law principles thereof.

		
	8.
	Severability. If any term or other provision of this Amendment is invalid, illegal or unenforceable, all other provisions of this Amendment shall remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party hereto.

		
	9.
	Amendment. No amendment, supplement, modification or cancellation of this Amendment shall be effective unless it shall be in writing and signed by each Party.  

[SIGNATURE PAGE FOLLOWS]

3

IN WITNESS WHEREOF, the Parties hereto have caused this Amendment to be executed by their duly authorized respective representatives as of the Amendment Effective Date.  
The Medicines Company
    

By:  /s/ William O’Connor        
Name:  William O'Connor      
Title:     CFO

Sandoz Inc.

By:  /s/ Peter Goldschmidt        
Name: Peter Goldschmidt          
Title:   President, Sandoz US
            Head of North America

4EX-4.1

 Exhibit 4.1 

AMENDMENT NO. 1 TO RIGHTS AGREEMENT 

This AMENDMENT NO. 1 TO THE RIGHTS AGREEMENT (this “Amendment”) is dated as of November 7, 2017 (the
“Effective Date”) and amends the Rights Agreement, dated as of January 6, 2017 (the “Rights Agreement”), by and between C&J Energy Services, Inc., a Delaware corporation (the
“Company”), and American Stock Transfer & Trust Company, LLC, as Rights Agent (the “Rights Agent”). Capitalized terms used in this Amendment and not otherwise defined have the meaning given to
them in the Rights Agreement. 
 RECITALS 

WHEREAS, in accordance with Section 24 of the Rights Agreement, at any time prior to the occurrence of a Section 9(a)(ii) Event, the
Company may in its sole and absolute discretion, and the Rights Agent shall if the Company so directs, supplement or amend any provision of the Rights Agreement in any respect without the approval of any holders of the Rights; and 

WHEREAS, the Rights Agent is hereby directed to join in this Amendment. 

AGREEMENT 
 NOW,
THEREFORE, in consideration of the premises and the mutual agreements set forth herein, the parties hereby agree as follows: 

1.    Amendment of the Rights Agreement. The definition of “Final Expiration Date” is hereby amended and
restated in its entirety as follows: 
 “Final Expiration Date” means the Close of Business on November 7,
2017. 
 2.    Amendment of Exhibits. The exhibits to the Rights Agreement shall be deemed to be restated to
reflect this Amendment, including all conforming changes. 
 3.    Other Amendment; Effect of Amendment. Except
as and to the extent expressly modified by this Amendment, the Rights Agreement and the exhibits thereto remain in full force and effect in all respects without any modification. This Amendment will be deemed an amendment to the Rights Agreement and
will become effective on the Effective Date. In the event of a conflict or inconsistency between this Amendment and the Rights Agreement and the exhibits thereto, the provisions of this Amendment will govern. 

4.    Counterparts. This Amendment may be executed in any number of counterparts and each of such counterparts will
for all purposes be deemed to be an original, and all such counterparts will together constitute one and the same instrument, it being understood that all parties need not sign the same counterpart. A signature to this Amendment transmitted
electronically (including by fax and .pdf) will have the same authority, effect and enforceability as an original signature. No party hereto may raise the use of such electronic transmission to deliver a signature, or the fact that any signature or
agreement or instrument was transmitted or communicated through such electronic transmission, as a defense to the formation of a contract, and each party forever waives any such defense, except to the extent such defense relates to lack of
authenticity. 
 5.    Severability. If any term, provision, covenant or restriction of this Amendment is held by
a court of competent jurisdiction or other authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Amendment will remain in full force and effect and will in no way be affected,
impaired or invalidated. 

 6.    Descriptive Headings. The descriptive headings of the several
Sections of this Amendment are inserted for convenience only and will not control or affect the meaning or construction of any of the provisions hereof. 

7.    Further Assurances. Each of the parties to this Amendment will cooperate and take such action as may be
reasonably requested by the other party in order to carry out the provisions and purposes of this Amendment, the Rights Agreement and the transactions contemplated hereunder and thereunder. 

8.    Governing Law. This Amendment will be deemed to be a contract made pursuant to the laws of the State of
Delaware and for all purposes shall be governed by and construed in accordance with the laws of such State applicable to contracts to be made and performed entirely within such State. 

[Signature Page Follows] 

  
 2 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed as of the
day and year first written above. 
  

			
	C&J ENERGY SERVICES, INC.
	
	 /s/ Danielle Hunter

	Name:	 	Danielle Hunter
	Title:	 	Executive Vice President, General Counsel, Chief Risk and Compliance Officer and Corporate Secretary

  
 3 

 
			
	 AMERICAN STOCK TRANSFER & TRUST

COMPANY, LLC

		
	By:	 	 /s/ Jennifer Donovan

	Name:	 	Jennifer Donovan
	Title:	 	SVP

  
 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}]]